Summary values of ANA, SMA and anti-SLA/LP for all studies and different subgroups.

¢: random-effects model; £: random-effects heterogeneity. 1/2/3: three groups (ANA/SMA/anti-SLA/LP), $/&: subgroups for European/Asian patients of autoimmune hepatitis, ‡/†: subgroups for immunoblot assay/non-immunoblot assay of detecting anti-SLA/LP. ANA = antinuclear antibodies, SMA = smooth muscle antibodies, anti-SLA/LP = antibodies to a soluble liver antigen/liver pancreas, No. = the number of included articles, LR+/− = positive/negative likelihood ratio, DOR = diagnostic odds ratio, CI = confidence interval.